Pancreatic Cancer Research

ResearcherChinese PLA General HospitalActive in the last 2 years

Weidong Han

Provisional: name at one institution (moderate confidence)As of 10 November 2026

Known by name at one institution; no external author ID yet. Name as it appears in ClinicalTrials.gov.

Their work

Papers
0
Trials
4 (principal investigator on 2)
Grants
0
Collaborators
1
Papers, trials and grants by year

2013: 1 trial · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 trial · 2019: none · 2020: none · 2021: none · 2022: 1 trial · 2023: none · 2024: none · 2025: 1 trial

Trials 4

  1. CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors Principal investigator NCT06939270↗
  2. An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC Principal investigator NCT05327582↗
  3. Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors Study director NCT03747965↗
  4. Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR) Study chair NCT01869166↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

  1. Jianqing Xu · 1 shared trial, 2025

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.